ovarian

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

April 07, 2026 08:05 ET  | Source: NextCure The U.S. Food and Drug Administration (FDA) has granted Fast Track designation…

3 weeks ago

Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer

SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of…

4 months ago